Skip to main content

#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, September 6 '25)

Image
By G.M.

 


    Antimicrob Agents Chemother

  1. YAMADA AY, de Souza AR, Madalosso G, de Assis DB, et al
    Emergence of carbapenem-resistant Acinetobacter baumannii clonal complex 2 in multiple hospitals in Sao Paulo state, Brazil.
    Antimicrob Agents Chemother. 2025 Jul 23:e0186524. doi: 10.1128/aac.01865.
    PubMed         Abstract available


    Biochemistry

  2. XIA H, Wei D, Guo Z, Chung LW, et al
    Machine Learning on the Impacts of Mutations in the SARS-CoV-2 Spike RBD on Binding Affinity to Human ACE2 Based on Deep Mutational Scanning Data.
    Biochemistry. 2025;64:3790-3800.
    PubMed         Abstract available


    Cell

  3. KONG W, Lu WJ, Dubey M, Suryawanshi RK, et al
    Neuroendocrine cells orchestrate regeneration through Desert hedgehog signaling.
    Cell. 2025;188:5020-5038.
    PubMed         Abstract available


    J Gen Virol

  4. POKHAREL BR, Majumdar N, Williams F, Dickerson A, et al
    SARS-CoV-2 infection of substantia nigra pars compacta induces expression of miR-330-5p at 10 days post-infection.
    J Gen Virol. 2025;106.
    PubMed         Abstract available

  5. BILLINGTON E, Di Genova C, Warren CJ, Thomas SS, et al
    Investigating factors driving shifts in subtype dominance within H5Nx clade 2.3.4.4b high pathogenicity avian influenza viruses.
    J Gen Virol. 2025;106:002150.
    PubMed         Abstract available


    J Infect

  6. STANLEY J, Arnold D, Hamilton F
    Genetic evidence supports trialling IL-6 inhibition in influenza.
    J Infect. 2025 Aug 31:106606. doi: 10.1016/j.jinf.2025.106606.
    PubMed        


    J Virol Methods

  7. LIM JY, Fiore A, Le B, Minzer C, et al
    Development and Validation of Novel Cell-free Direct Neutralization Assay for SARS-CoV-2.
    J Virol Methods. 2025;338:115201.
    PubMed         Abstract available

  8. WAGNER DD, Nabakooza G, Momin N, Marine RL, et al
    Illumina MiSeq and iSeq platforms yield comparable results for viral genomic sequencing.
    J Virol Methods. 2025;338:115202.
    PubMed         Abstract available

  9. LESCHINSKY G, Dexter WA, Leschinsky B, Trolinger J, et al
    Design and feasibility of a novel personal protection device against airborne pathogens for everyday use.
    J Virol Methods. 2025;338:115203.
    PubMed         Abstract available

  10. MORRISON EN, Harnden M, Boisvert E, Wilson AE, et al
    Towards efficient and targeted sampling of primary respiratory diseases from wastewater in congregate settings for seniors: Empowering high-risk demographics with prospective health threat data.
    J Virol Methods. 2025;338:115212.
    PubMed         Abstract available

  11. KATSANOVSKAJA K, Marchesin F, Ujetz J, Ijaz S, et al
    Beyond the limits of conventional 'endpoint' ELISA and rescuing the signal with lag k-ELISA.
    J Virol Methods. 2025;338:115231.
    PubMed         Abstract available

  12. ZENG L, Wang Y, Xiang B, Lin J, et al
    The dynamics of common respiratory pathogens in southern china under the context of COVID-19 pandemic and prediction of mycoplasma pneumonia (2018-2023).
    J Virol Methods. 2025;338:115240.
    PubMed         Abstract available

  13. GONZALEZ G S, Dias A, Reis R, Villalba S, et al
    Effective RNA extraction with readily available reagents: A comparative analysis of alternative protocols.
    J Virol Methods. 2025;338:115242.
    PubMed         Abstract available

  14. NAPOLITAN A, Mazzacan E, Fonti N, Tomasoni S, et al
    Cryopreservation of chicken and duck tracheal rings and precision-cut lung slices: A promising tool for the rapid characterization of avian influenza viruses.
    J Virol Methods. 2025;339:115257.
    PubMed         Abstract available


    Lancet

  15. ANDERSON CS, Hua C, Wang Z, Wang C, et al
    Influenza vaccination to improve outcomes for patients with acute heart failure (PANDA II): a multiregional, seasonal, hospital-based, cluster-randomised, controlled trial in China.
    Lancet. 2025 Aug 28:S0140-6736(25)01485-0. doi: 10.1016/S0140-6736(25)01485.
    PubMed         Abstract available

  16. BHATT AS, Vardeny O
    Influenza vaccination in heart failure: a shot worth taking?
    Lancet. 2025 Aug 28:S0140-6736(25)01679-4. doi: 10.1016/S0140-6736(25)01679.
    PubMed        


    MMWR Morb Mortal Wkly Rep

  17. TOBOLOWSKY FA, Morris E, Castro L, Schaff T, et al
    Highly Pathogenic Avian Influenza A(H5N1) Virus Infection in a Child with No Known Exposure - San Francisco, California, December 2024-January 2025.
    MMWR Morb Mortal Wkly Rep. 2025;74:522-527.
    PubMed         Abstract available


    N Engl J Med

  18. JOHANSEN ND, Modin D, Loiacono MM, Harris RC, et al
    High-Dose Influenza Vaccine Effectiveness against Hospitalization in Older Adults.
    N Engl J Med. 2025 Aug 30. doi: 10.1056/NEJMoa2509907.
    PubMed         Abstract available

  19. PARDO-SECO J, Rodriguez-Tenreiro-Sanchez C, Gine-Vazquez I, Mallah N, et al
    High-Dose Influenza Vaccine to Reduce Hospitalizations.
    N Engl J Med. 2025 Aug 30. doi: 10.1056/NEJMoa2509834.
    PubMed         Abstract available


    Pediatrics

  20. FREE RJ, Patel K, Taylor CA, Sachdev D, et al
    Hospitalization for COVID-19 and Risk Factors for Severe Disease Among Children: 2022-2024.
    Pediatrics. 2025;156:e2025072788.
    PubMed         Abstract available

  21. ALLEN AJ, Nguyen N, Lorman V, Maltenfort M, et al
    Respiratory and Other Infections Following COVID.
    Pediatrics. 2025;156:e2024068280.
    PubMed         Abstract available

  22. GOLDSTEIN LA, Michaels MG, Salthouse A, Toepfer AP, et al
    Human Metapneumovirus and Respiratory Syncytial Virus in Children: A Comparative Analysis.
    Pediatrics. 2025;156:e2024070218.
    PubMed         Abstract available

  23. BODY A, Lal L, Downie P, Anazodo A, et al
    Immune Response to COVID-19 Vaccination in Children With Cancer.
    Pediatrics. 2025 Aug 8:e2024070209. doi: 10.1542/peds.2024-070209.
    PubMed         Abstract available


    PLoS Biol

  24. HOLMES KE, Ferreri LM, Elie B, Ganti K, et al
    Viral expansion after transfer is a primary driver of influenza A virus transmission bottlenecks.
    PLoS Biol. 2025;23:e3003352.
    PubMed         Abstract available


    PLoS Comput Biol

  25. TORRES-FLOREZ S, Flores Anato JL, He JH, Portilla VG, et al
    Evaluating COVID-19 vaccination policy in Quebec (Canada) using a data-driven dynamic transmission model.
    PLoS Comput Biol. 2025;21:e1013207.
    PubMed         Abstract available

  26. REYNE B, Kamiya T, Djidjou-Demasse R, Alizon S, et al
    Leaky or polarised immunity: Non-Markovian modelling highlights the impact of immune memory assumptions.
    PLoS Comput Biol. 2025;21:e1013399.
    PubMed         Abstract available


    PLoS One

  27. HBID Y, Stanley K, Wolfe CDA, Bhalla A, et al
    Stroke care in the United Kingdom before, during, and after the COVID-19 lockdowns: A retrospective nationwide cohort study.
    PLoS One. 2025;20:e0330903.
    PubMed         Abstract available

  28. STOLARCZUK JE, Sosa M, Pike M, Baranoff A, et al
    Transplacental transfer of maternal SARS-CoV-2 antibodies in dichorionic and monochorionic twin pregnancies.
    PLoS One. 2025;20:e0328137.
    PubMed         Abstract available

  29. VISKUPIC F, Wiltse DL, Stenvig TE
    Nurses' attitudes about RSV vaccination for pregnant women and infants: Evidence from a cross-sectional survey.
    PLoS One. 2025;20:e0331326.
    PubMed         Abstract available

  30. ARIK A, Cairns AJG, Streftaris G
    Cancer disparities: Projection, COVID-19, and scenario-based diagnosis delay impact.
    PLoS One. 2025;20:e0330752.
    PubMed         Abstract available

  31. SONG J, Jeon J
    Deep momentum networks with market trend dynamics.
    PLoS One. 2025;20:e0331391.
    PubMed         Abstract available

  32. BI W, Shen Y, Ji Y, Du Y, et al
    Who continued travelling by bus in different periods of COVID-19? A data-driven analysis from Shanghai, China.
    PLoS One. 2025;20:e0328700.
    PubMed         Abstract available

  33. ATHA L, Ryde E, Burke L, Brady S, et al
    Investigating the use of a one-page infographic to improve recruitment and retention to the BASIL+ randomised controlled trial: A Study Within a Trial (SWAT).
    PLoS One. 2025;20:e0320821.
    PubMed         Abstract available

  34. SEMANCIK CS, Fantin R, Butt J, Abdelnour A, et al
    SARS-CoV-2 antibody and neutralization dynamics among persons with natural- and vaccine-induced exposures.
    PLoS One. 2025;20:e0331212.
    PubMed         Abstract available

  35. RITCHWOOD TD, Burton K, Wynn M
    Before the wave: Exploring early perspectives on COVID-19 self-testing among African Americans in Eastern North Carolina.
    PLoS One. 2025;20:e0330513.
    PubMed         Abstract available

  36. EVANS LV, Bonz JW, Buck S, Gerwin JN, et al
    An adaptive simulation intervention decreases emergency physician physiologic stress while caring for patients during COVID-19: A randomized clinical trial.
    PLoS One. 2025;20:e0331488.
    PubMed         Abstract available

  37. TAN C, Zhong J, Yang D, Huang W, et al
    Forecasting and analysing global average temperature trends based on LSTM and ARIMA models.
    PLoS One. 2025;20:e0330645.
    PubMed         Abstract available

  38. MULLER-POLYZOU R, Reuter-Oppermann M
    Radiotherapy continuity for cancer treatment: Lessons learned from natural disasters.
    PLoS One. 2025;20:e0308056.
    PubMed         Abstract available

  39. SHANKAR R, Wang L, Hoe HS, Fong LM, et al
    Cost-effectiveness of virtual emergency care models: A protocol for a systematic review.
    PLoS One. 2025;20:e0330946.
    PubMed         Abstract available

  40. CATES ZP, Facciuolo A, Scruten E, Kusalik A, et al
    Peptide immunoarrays for rationale development of vaccines with enhanced cross-reactivity.
    PLoS One. 2025;20:e0330741.
    PubMed         Abstract available

  41. OKYERE E, Marfoh K, Kabukeinamala D, Goundar R, et al
    Benefits and challenges: Qualitative exploration of women's experiences during the COVID-19 pandemic in Fiji.
    PLoS One. 2025;20:e0331794.
    PubMed         Abstract available

  42. KAMADA N, Hagiya H, Kutsuna S
    Impact of COVID-19 on the awareness and interest in infectious disease specialization among Japanese medical students.
    PLoS One. 2025;20:e0329451.
    PubMed         Abstract available

  43. NAGY A, Cernikova L, Sedlak K
    Genetic data and meteorological conditions suggesting windborne transmission of H5N1 high-pathogenicity avian influenza between commercial poultry outbreaks.
    PLoS One. 2025;20:e0319880.
    PubMed         Abstract available

  44. XIE F, Wei H
    Characteristics and dynamic evolution of inter-industry volatility spillovers in China's stock market.
    PLoS One. 2025;20:e0330599.
    PubMed         Abstract available

  45. SALAZAR-GRANIZO YE, Caparros-Gonzalez RA, Puente-Fernandez D, Hueso-Montoro C, et al
    Highly stressful global event affecting health sciences students: A longitudinal qualitative study.
    PLoS One. 2025;20:e0331694.
    PubMed         Abstract available

  46. HAN D, Choi CG
    The spatial dynamics of urban vegetation and housing prices: Insights from pre- and post-pandemic Chicago using OLS and MGWR models.
    PLoS One. 2025;20:e0330932.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  47. ROWNTREE LC, Allen LF, Hagen RR, McQuilten HA, et al
    HLA-B*15:01-positive severe COVID-19 patients lack CD8(+) T cell pools with highly expanded public clonotypes.
    Proc Natl Acad Sci U S A. 2025;122:e2503145122.
    PubMed         Abstract available


    Vaccine

  48. IRVING SA, Groom HC, Belongia EA, Crane B, et al
    Differences in influenza vaccination coverage by race and ethnicity across age groups in the Vaccine Safety Datalink, 2017-18 through 2022-23 influenza seasons.
    Vaccine. 2025;64:127667.
    PubMed         Abstract available

  49. ZHOU Y, Wang H, Chu L, Chen K, et al
    Influenza vaccination hesitancy and decision between parental and grandparental caregivers of preschoolers: a comparative study.
    Vaccine. 2025;64:127696.
    PubMed         Abstract available
Labels:

Comments

Post a Comment

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

By G.M.
{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...
Post a Comment
Read more »

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

By G.M.
Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...
Post a Comment
Read more »

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

By G.M.
Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...
Post a Comment
Read more »